Merz to Present New Aesthetics Clinical Data at AMWC 2019

Merz, a global leader in aesthetics and neurotoxins, announced today
that clinical data on the use of the Merz Aesthetics portfolio,
including Belotero^®, Cellfina^®, Radiesse^®,
Ultherapy^® and Botulinum Toxin will be featured in oral and
poster presentations at the 2019 Aesthetic & Anti-Aging Medicine World
Congress (AMWC), to be held from Thursday, April 4 to Saturday, April 6,
2019 in Monte-Carlo, Monaco.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190404005258/en/

In addition to the poster presentations listed below, Merz Aesthetics is
also sponsoring the Symposium event Early Intervention Meets
Beautification – Treating the Social Media Generation, to be held on
Friday, April 5 at 14.00h – 16.00h, Auditorium Prince Pierre. The
session will include live injections and treatment insights from five
international expert speakers:

• Dr. Rolf Bartsch – Plastic Surgeon, Austria
• Dr. Sabrina Fabi – Dermatologist, USA
• Prof. Dr. Martina Kerscher – Dermatologist, Germany
• Dr. Jani van Loghem – Aesthetic Physician, The Netherlands
• Dr. Sonja Sattler – Dermatologist, Germany
• Marie Doppelhofer – Blogger and entrepreneur, Austria

Oral Presentations

• Restorative properties of hydroxylapatite (Regenerative Aesthetics
  Session). Kate Goldie, MBChB – European Medical Aesthetics Ltd,
  London, UK; Sabrina Fabi, MD, Cosmetic Laser Dermatology, San Diego,
  USA. Thursday, April 4, 10:00-12:00h, Auditorium Camille Blanc
• Elements of the face attractiveness and balance (Fillers: Natural
  Results and Attractiveness Session). Dr. Jani van Loghem, MD – Falck
  Clinic, Amsterdam, The Netherlands. Thursday, April 4,
  14:00-16:00h, Auditorium Prince Pierre
• Study with controlled subcision, calcium hydroxylapatite and
  microfocused ultrasound with visualization: What is the best algorithm
  for combination to improve cellulite appearance (Rubbish and Reality
  on Combined Treatments Session). Gabriela Casabona, MD – Ocean Clinic,
  Marbella. Saturday, April 6, 9:00-10:30h, Auditorium Camille
  Blanc

Poster Presentations

Posters will be available for viewing at the Poster Zone on Level 2,
outside of the Camille Blanc Auditorium, from Thursday, April 4 to
Saturday, April 6.

Botulinum Toxin

• IncobotulinumtoxinA: A unique and pure formulation of botulinum
  neurotoxin type A for use in aesthetic and therapeutic medicine. Ada
  Trindade de Almeida, MD – Hospital do Servidor Municipal de São Paulo,
  São Paulo, Brazil.
• Comparison of incobotulinumtoxinA to botulinum neurotoxin type A
  formulations in Asia. Jürgen Frevert, PhD – Formerly of Merz
  Pharmaceuticals GmbH, Frankfurt, Germany.
• Escalating doses of incobotulinumtoxinA for extended treatment of
  glabellar frown lines: safety and efficacy results from a randomized,
  double-blind study. Corey Maas, MD – The Maas Clinic, San Francisco,
  CA, US.
• Safety, tolerability, and efficacy of repeat-dose injections of
  incobotulinumtoxinA in the treatment of upper facial lines: results
  from a prospective, open-label, phase III study. Tanja Fischer, MD –
  Haut- & Lasercentrum, Potsdam, Germany.
• Combined post-operative scar treatment with incobotulinumtoxinA and
  microneedling to improve the appearance and functionality of scarring
  following surgical removal of facial skin tumors and flap
  reconstruction. Gabriela Casabona, MD – Ocean Clinic, Marbella, Spain
• Decrease in therapeutic effect among botulinum toxin type A agents:
  Analysis of the FDA adverse event reporting system database. Rashid
  Kazerooni, PharmD, MS, BCPS – Merz North America, Raleigh, NC, US

Belotero^®

• Open label multicenter post-market clinical follow-up to confirm the
  performance and the safety of CPM^®-HA20 in facial skin
  revitalization. Martina Kerscher, MD, PhD – University of Hamburg,
  Hamburg, Germany.
• Cohesive polydensified matrix crosslinked hyaluronic acid volumizing
  gel: An MRI and CT study. Patrick Micheels, MD – Private Practice,
  Geneva, Switzerland

Radiesse^®

• Diluted and Hyperdiluted Calcium Hydroxylapatite for Skin Tightening:
  Guidelines from a Global Consensus Panel. Kate Goldie, MBChB –
  European Medical Aesthetics Ltd, London, UK
• Radiological evaluation of calcium hydroxylapatite implantation to
  correct volume loss in the dorsum of the hand. Amir Moradi, MD –
  Private Practice, Vista, CA, US
• CaHA microspheres: Contact with fibroblasts and amount of spheres are
  key factors for collagen stimulation. Bartosch Nowag – Merz
  Pharmaceuticals GmbH, Frankfurt, Germany
• Calcium hydroxylapatite: A safety review. Jonathan A. Kadouch, MD, PhD
  – ReSculpt Clinic, Amsterdam, The Netherlands

Ultherapy^®

• Upper Body Lifting and Tightening with Calcium Hydroxylapatite and
  Microfocused Ultrasound with Visualization. Jani van Loghem, MD –
  Falck Clinic, Amsterdam, The Netherlands
• Differentiation of microfocused ultrasound with visualization
  treatment using a customized management protocol of see-plan-treat.
  Julia Sevi, MBChB – Aesthetic Health, Leeds, UK
• Microfocused Ultrasound with Visualization: Treatment Plans and
  Comfort Management in Real-World Practice. Amanda K. Doyle, MD –
  Russak Dermatology, New York, NY, US

Cellfina^®

• Multicenter Pivotal Study of the Safety and Effectiveness of a Tissue
  Stabilized-Guided Subcision Procedure for the Treatment of Cellulite -
  5 Year Update. Michael S. Kaminer, SkinCare Physicians, Chestnut Hill,
  MA, US

Copyright © 2019 Merz Pharma GmbH & Co. KGaA. All rights reserved. MERZ,
MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz
Pharma GmbH & Co. KgaA.

About Merz

Merz is a global, family-owned aesthetics and neurotoxin company based
in Frankfurt, Germany. Privately-held for 110 years, the company is
distinguished by its commitment to innovation, long-term perspective and
focus on profitable growth. In addition to its comprehensive portfolio
of medical aesthetics products across the device, injectable and
skincare categories, Merz also develops neurotoxin therapy to treat
neurologically-induced movement disorders. In fiscal year 2017/18, Merz
generated revenue of EUR 1.024,4 million; the company has a total
workforce of 3,151 employees worldwide and a direct presence in 28
countries. More information is available at www.merz.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190404005258/en/